Business Wire

The Rock-It Company Expands Fine Art Logistics Capabilities of DIETL Through Acquisition of Several Strategic Infrastructure Services

5.1.2026 15:00:00 CET | Business Wire | Press release

Share

The acquisition strengthens DIETL’s fine art logistics operations through expanded access to specialized storage, handling and customs services.

The Rock-It Company announced today that DIETL has acquired multiple fine art logistics specialists, strengthening its infrastructure and expanding access to specialized services across key U.S. art markets.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260105175923/en/

The Rock-It Company Expands Fine Art Logistics Capabilities of DIETL Through Acquisition of Several Strategic Infrastructure Services

The acquired companies include Delaware Freeport, Delaware National Art Company, Techno Export, and Registrar Technologies. Together, these businesses add depth across fine art storage, handling, packing, crating, installation support, customs brokerage, and technology-enabled logistics services, complementing DIETL’s existing operations.

Delaware Freeport, a provider of high-security, climate-controlled fine art storage, will operate as Delaware Freeport by DIETL, joining DIETL’s portfolio of trusted storage access points for collectors and institutions. As a U.S.-based foreign trade zone and freeport dedicated to fine art, Delaware Freeport provides added flexibility in how high-value works are managed and cared for over time.

Delaware National Art Company will operate as DNA by DIETL, delivering specialized art transportation, custom crating, fine art storage, and exhibition support with climate-controlled care and sustainable solutions for artists, galleries, and institutions.

The remaining acquired companies expand DIETL’s regional reach, technical expertise, and long-term platform capabilities. They will be incorporated into DIETL’s offering over time as part of the company’s continued investment in growth and operational excellence.

“Bringing these specialized businesses into the DIETL organization further strengthens our ability to support the fine art market with precision, care, and expertise,” said Daniel Rosenthal, President and Chief Executive Officer of The Rock-It Company. “We are excited to continue investing in DIETL’s growth and to deepen the services we provide to collectors, galleries, and institutions.”

The acquisition follows DIETL’s recent expansion into the Middle East with the opening of a new fine art storage and logistics facility in Dubai, UAE, supporting the company’s continued global growth in specialized handling, logistics, and storage of fine art and related assets.

ABOUT DIETL

DIETL is a leading provider of fine art and luxury good logistics, delivering specialized freight forwarding, customs brokerage and secure, climate-controlled storage for some of the world’s most valuable and irreplaceable collections. Built on more than three decades of expertise, DIETL is trusted to manage the most complex logistical challenges across the global art market.

With international reach and access, DIETL serves institutions, galleries, auction houses, collectors, and cultural organizations of every scale. The company is committed to operational excellence with a focus on sustainability solutions, offering its clients environmentally responsible packaging and shipping alternatives, and fostering a culture that supports the communities in which it operates.

ABOUT THE ROCK-IT COMPANY

The Rock-It Company (formerly Global Critical Logistics) is a global leader in mission-critical specialty logistics, trusted to move irreplaceable assets and power extraordinary moments across Live Events and Luxury Goods. Built on a 47-year legacy, Rock-It delivers multimodal freight forwarding, event logistics planning, specialized packing and storage, customs and ATA carnet services, insurance, on-site support, and more.

Rock-It manages the logistics behind concert touring, major sporting events, broadcast productions, film and media, corporate events, experiential activations, rapid response and infrastructure, and the transport and protection of fine art, rare automobiles, and other priceless collections. With access across 160+ countries and with more than 10,000 missions each year, Rock-It serves a diverse list of partners including the FIFA World Cup 2026, the Pebble Beach Concours D’Elegance, RM Sotheby’s, leading hypercar OEMs, multiple Olympic committees, leagues and federations, and other leading brands across the globe.

ABOUT CERTAIN ACQUIRED COMPANIES

Delaware Freeport (“DFP”) was founded in 2015 and offers discrete, state-of-the-art, and cost-effective museum-quality fine art storage and highly skilled technical services including condition reporting, installation, viewing, and repacking. It is the only fine-art dedicated Foreign Trade Zone warehouse in the US. Its associate company Delaware National Art Company LLC (“DNA”) was started in 2018 in Clifton, NJ, and provides expert art handling, trucking, and crating services to the NYC region, also linking DFP to the world with its weekly NJ-DE fine art shuttle service. Registrar Technologies LLC was initially created to solve art world logistical problems with customized tech solutions and has been utilized exclusively by DIETL since 2016. Techno Export, Inc. has been providing licensed customs brokerage services for the fine art import and export shipments since 1981.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260105175923/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye